Osnat Elyashiv

4PUBLICATIONS
7CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 10, 2024
The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients.

Osnat Elyashiv, Natalie Aleohin, Zohar Migdan

|Oct 11, 2022
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.

Rowan E Miller, Osnat Elyashiv, Karim H El-Shakankery

|Jun 14, 2021
Frontline Maintenance Treatment for Ovarian Cancer.

Osnat Elyashiv, Yien Ning Sophia Wong, Jonathan A Ledermann

|Oct 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.

Osnat Elyashiv, Jonathan Ledermann, Gita Parmar

Pageof 1

Frequent Collaborators

3 joint publications

Jonathan Ledermann

1 joint publications

Charlie Gourley

1 joint publications

Yien Ning Sophia Wong

1 joint publications

Karim H El-Shakankery